
    
      This research study involves an investigational drug combination not approved by the FDA (the
      U.S. Food and Drug Administration) for your kidney cancer.

      The names of the study drugs in this investigational combination are:

        -  Cabozantinib

        -  Nivolumab

        -  Ipilimumab

      The research study procedures include screening for eligibility, study treatment, participant
      evaluations and safety follow-up visits, in addition to general health status follow-up after
      study treatment.

      It is expected that about 40 people will take part in this research study.
    
  